Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Infusion of two unexpanded cord blood units · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| Active | EXPERIMENTAL | Infusion of one MPC expanded cord unit and one unexpanded cord unit. |
| Control | ACTIVE_COMPARATOR | Infusion of two unexpanded cord blood units. |
| Name | Type | Description |
|---|---|---|
| Infusion of one MPC expanded cord unit and one unexpanded cord unit | BIOLOGICAL | Infusion of one MPC expanded cord unit and one unexpanded cord unit. |
| Infusion of two unexpanded cord blood units. | BIOLOGICAL | Umbilical Cord Blood. |
Inclusion Criteria: * Patient must have one of the following: * Acute myelogenous leukemia (AML) in complete morphological remission at study screening (Complete Remission with Incomplete Platelet Recovery (CRp) acceptable). * Acute lymphoblastic leukemia (ALL) in complete morphological remiss...
Infusion of two unexpanded cord blood units is an investigational therapy being studied for use in patients with hematologic malignancies, including Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, and Hodgkin's Disease. It is administered as part of a stem cell transplantation procedure.
Infusion of two unexpanded cord blood units is being developed by Mesoblast Limited, a biopharmaceutical company listed on the stock exchange under the ticker symbol MESO.
Infusion of two unexpanded cord blood units is in Phase 3 clinical development. It is an investigational therapy and has not been approved by regulatory authorities. One Phase 3 trial has been completed.
Infusion of two unexpanded cord blood units was studied in a completed Phase 3 clinical trial registered as NCT01854567. This trial evaluated the therapy in 49 patients with hematologic malignancies, including Acute Myelogenous Leukemia, and was conducted in the United States.
Infusion of two unexpanded cord blood units is distinct from expanded cord blood cells. The Phase 3 trial NCT01854567 studied umbilical cord blood cells expanded with mesenchymal precursor cells (MPCs) for transplantation, while the therapy name refers to the use of two unexpanded cord blood units.